Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 Net Margin % is 5.88% as of Mar. 2026, which is 64% below its 10-year median of 16.25. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 86.14% on this metric.
The historical rank and industry rank for Invicta Diagnostic's Net Margin % or its related term are showing as below:
NSE:INVICTA'
s Net Margin % Range Over the Past 10 Years
Min: 15.17 Med: 16.25 Max: 23.76
Current: 15.17
NSE:INVICTA's Net Margin % is ranked better than 86.14% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.705
vs NSE:INVICTA: 15.17
Invicta Diagnostic (NSE:INVICTA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Invicta Diagnostic Net Margin % Related Terms
Invicta Diagnostic Net Margin % Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic Net Margin % Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
Net Margin %
23.76
16.25
15.17
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
Net Margin %
0.00
0.00
23.60
5.88
NSE:INVICTA vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Net Margin % distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a Net Margin % of 5.88% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Invicta Diagnostic and its competitors. This is 64% below median its historical median of 16.25. Over the past decade, Invicta Diagnostic's Net Margin % has ranged from 15.17 to 23.76. According to the industry distribution chart, Invicta Diagnostic ranks #28 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 13.9%.
Is Invicta Diagnostic's Net Margin % too high?
Invicta Diagnostic's current Net Margin % of 5.88% is 64% below median its 10-year median of 16.25. Over the past 10 years, this metric has ranged from a low of 15.17 to a high of 23.76. Based on the distribution chart, Invicta Diagnostic ranks #28 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #28 out of 202 companies for Net Margin %. This places Invicta Diagnostic in the top 14% of its industry — outperforming the majority of peers. Historically, Invicta Diagnostic's own Net Margin % has ranged from 15.17 to 23.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Invicta Diagnostic and its competitors. Invicta Diagnostic's current Net Margin % is 5.88%, which is 64% below median its own 10-year median of 16.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Net Margin % of 5.88%. The current Net Margin % is 5.88%, which is 64% below median its 10-year median of 16.25. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Net Margin % is 5.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
